国家: 加拿大
语言: 英文
来源: Health Canada
VALGANCICLOVIR (VALGANCICLOVIR HYDROCHLORIDE)
AURO PHARMA INC
J05AB14
VALGANCICLOVIR
50MG
POWDER FOR SOLUTION
VALGANCICLOVIR (VALGANCICLOVIR HYDROCHLORIDE) 50MG
ORAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0147203002; AHFS:
APPROVED
2023-02-16
_AURO-VALGANCICLOVIR PRODUCT MONOGRAPH _ Page 1 of 52 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR AURO-VALGANCICLOVIR Valganciclovir Powder for Oral Solution Powder for solution, 50 mg/mL when reconstituted valganciclovir (as valganciclovir hydrochloride), Oral Antiviral Agent AURO PHARMA INC., 3700 Steeles Avenue West, Suite # 402 Woodbridge, Ontario, L4L 8K8, Canada Submission Control Number: 255848 Date of Initial Authorization: February 14, 2023 _AURO-VALGANCICLOVIR PRODUCT MONOGRAPH _ Page 2 of 52 RECENT MAJOR LABEL CHANGES N/A TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .............................................................................................. 2 TABLE OF CONTENTS ................................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION........................................................................ 4 1 INDICATIONS ......................................................................................................................... 4 1.1 Pediatrics ................................................................................................................ 4 1.2 Geriatrics ................................................................................................................ 4 2 CONTRAINDICATIONS............................................................................................................ 4 4 DOSAGE AND ADMINISTRATION ........................................................................................... 5 4.1 Dosing Considerations ............................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment .......................................................... 6 4.3 Reconstitution Oral Solutions:.................................................................................. 8 4.4 Administra 阅读完整的文件